Quercetin-Arctigenin Co-Treatment Induces Mitochondrial Dysfunction and Apoptotic Cell Death Through Metabolic Stress

Moon-Kyun Cho1,2, Sang-Han Lee1,3, Hae-Seon Nam1,4

  • 1Division of Molecular Cancer Research, Soonchunhyang Medical Research Institute, Soonchunhyang University, Cheonan 31511, Republic of Korea.

Insights

Quercetin (QUE) and arctigenin (ATG) synergistically inhibit malignant mesothelioma cell growth by inducing metabolic stress and apoptosis. This combination therapy targets cancer cell metabolism and mitochondrial function, offering a promising strategy for this aggressive cancer.

Area of Science:

  • Oncology
  • Cell Biology
  • Metabolomics

Background:

  • Malignant mesothelioma is an aggressive cancer with limited treatment options.
  • Targeting metabolic vulnerabilities is a key strategy for novel cancer therapies.
  • Natural polyphenols like quercetin and arctigenin show potential in modulating cancer cell metabolism and apoptosis.

Purpose of the Study:

  • To investigate the combined anticancer effects of quercetin (QUE) and arctigenin (ATG) in human malignant mesothelioma cells.
  • To explore the underlying mechanisms, including metabolic stress and apoptotic pathways.

Main Methods:

  • Malignant mesothelioma (MSTO-211H) and non-malignant (MeT-5A) cells were treated with QUE and ATG.
  • Cell viability, ATP levels, caspase activity, and apoptosis were assessed.
  • Western blotting was used to analyze apoptosis-related proteins and mitochondrial oxidative phosphorylation (OXPHOS) complexes.

Main Results:

  • Combined QUE and ATG treatment significantly reduced mesothelioma cell viability with synergistic effects.
  • Co-treatment decreased intracellular ATP levels and increased caspase-3/7 activity, indicating metabolic stress and apoptosis.
  • Apoptotic cell populations increased, with reduced Mcl-1/Bcl-xL and increased cleaved caspase-3/PARP.
  • AMPK phosphorylation and altered OXPHOS protein expression suggest mitochondrial functional changes.

Conclusions:

  • Quercetin and arctigenin co-treatment induces synergistic apoptotic cell death in malignant mesothelioma.
  • The combination therapy is associated with metabolic stress and alterations in mitochondrial function.
  • This approach presents a potential novel therapeutic strategy for malignant mesothelioma.